Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 28, Number 6—June 2022

Rapid Increase of Community SARS-CoV-2 Seroprevalence during Second Wave of COVID-19, Yaoundé, Cameroon

Francis Ateba Ndongo, Emilande GuichetComments to Author , Eric Donald Mimbé, Justin Ndié, Raphael Pelloquin, Marie Varloteaux, Livo Esemu, Mireille Mpoudi-Etame, Nadine Lamare, Ginette Edoul, Rodrigue Kamga Wouambo, Dowbiss Meta Djomsi, Marcel Tongo, Félicité Naah Tabala, Rogacien Kana Dongmo, Mamadou Saliou Kalifa Diallo, Julie Bouillin, Guillaume Thaurignac, Ahidjo Ayouba, Martine Peeters, Eric Delaporte, Anne-Cécile Zoung-Kanyi Bissek, and Eitel Mpoudi-Ngolé
Author affiliations: Ministry of Public Health of Cameroon Division of Operational Research in Health, Yaoundé, Cameroon (F. Ateba Ndongo, J. Ndié, F.N. Tabala, R.K. Dongmo, A.-C. Zoung-Kanyi Bissek); Recherches Translationnelles sur le VIH et les Maladies Infectieuses, University of Montpellier, Institut de Recherche pour le Développement, Institut National de la Santé et de la Recherche Médicale, Montpellier, France (E. Guichet, R. Pelloquin, M.S.K. Diallo, J. Bouillin, G. Thaurignac, A. Ayouba, M. Peeters, E. Delaporte); French National Agency for Research on AIDS and Infectious Diseases, Cameroon Site, Central Hospital of Yaoundé, Yaoundé (E.D. Mimbé, M. Varloteaux, A.-C. Zoung-Kanyi Bissek, E. Mpoudi-Ngolé); Centre de Recherche sur les Maladies Emergentes et Réémergentes, Yaoundé (L. Esemu, N. Lamare, G. Edoul, R. Kamga Wouambo, D. Meta Djomsi, M. Tongo, E. Mpoudi-Ngolé); Military Hospital of Yaoundé, Yaoundé (M. Mpoudi-Etame)

Main Article

Table 2

Seroprevalence of SARS-COV-2 antibodies by age, sex, and medical history in 2 consecutive population-based surveys during second wave of COVID-19, Yaoundé, Cameroon, 2021*

Characteristic Participants, survey 1, January 27–February 6
Participants, survey 2, April 24–May 19
Total no. No. (%) positive % Positive (95% CI) p value Total no. No. (%) positive % Positive (95% CI) p value
Age group, y 0.002 <0.001
0–19 236 31 13.1 (9.3–18.3) 468 200 42.7 (38.3–47.3)
20–39 276 71 25.7 (20.8–31.4) 440 263 59.8 (55.0–64.4)
22.9 (17.5–29.2)

62.8 (57.3–68.0)

Sex 0.773 0.942
F 423 89 18.5 (14.8–22.9) 718 392 51.0 (47.1–54.8)
19.0 (14.8–24.1)

51.6 (47.0–56.1)

No. symptoms 0.688 0.288
0 271 70 22.5 (17.8–28.0) 776 424 51.8 (48.1–55.5)
1–2 157 26 12.8 (7.5–21.0) 257 129 47.8 (41.6–54.0)
3–5 134 27 22.5 (13.5–35.2) 167 92 53.9 (45.6–61.9)
18.4 (8.4–35.9)

57.5 (39.0–75.7)

Hospitalization 0.150 0.487
Yes 28 6 10.7 (4.4–23.6) 12 8 51.0 (17.3–83.9)
18.0 (12.8–24.7)

50.1 (45.1–55.2)

Total 722 150 18.6 (15.7–21.7) 1 228 664 51.3 (48.3–54.2)

*Overall seroprevalence estimate was age-standardized, based on available demographic data (12).

Main Article

  1. World Health Organization. Coronavirus (COVID-19) dashboard [cited 2021 Nov 26].
  2. Africa Centres for Disease Control and Prevention. Coronavirus disease 2019 (COVID-19) [cited 2021 Nov 26].
  3. Chisale  MRO, Ramazanu  S, Mwale  SE, Kumwenda  P, Chipeta  M, Kaminga  AC, et al. Seroprevalence of anti-SARS-CoV-2 antibodies in Africa: A systematic review and meta-analysis. Rev Med Virol. 2022;32:e2271. DOIPubMedGoogle Scholar
  4. Sagara  I, Woodford  J, Kone  M, Assadou  MH, Katile  A, Attaher  O, et al. Rapidly increasing SARS-CoV-2 seroprevalence and limited clinical disease in three Malian communities: a prospective cohort study. Clin Infect Dis. 2022;74:10308. DOIPubMedGoogle Scholar
  5. Fryatt  A, Simms  V, Bandason  T, Redzo  N, Olaru  ID, Ndhlovu  CE, et al. Community SARS-CoV-2 seroprevalence before and after the second wave of SARS-CoV-2 infection in Harare, Zimbabwe. EClinicalMedicine. 2021;41:101172. DOIPubMedGoogle Scholar
  6. Kleynhans  J, Tempia  S, Wolter  N, von Gottberg  A, Bhiman  JN, Buys  A, et al.; PHIRST-C Group. PHIRST-C Group. SARS-CoV-2 seroprevalence in a rural and urban household cohort during first and second waves of infections, South Africa, July 2020–March 2021. Emerg Infect Dis. 2021;27:30209. DOIPubMedGoogle Scholar
  7. World Health Organization. Seroepidemiological investigation protocol for coronavirus 2019 (COVID-19) infection [cited 2021 Nov 3].
  8. Ayouba  A, Thaurignac  G, Morquin  D, Tuaillon  E, Raulino  R, Nkuba  A, et al. Multiplex detection and dynamics of IgG antibodies to SARS-CoV2 and the highly pathogenic human coronaviruses SARS-CoV and MERS-CoV. J Clin Virol. 2020;129:104521. DOIPubMedGoogle Scholar
  9. Nkuba Ndaye  A, Hoxha  A, Madinga  J, Mariën  J, Peeters  M, Leendertz  FH, et al. Challenges in interpreting SARS-CoV-2 serological results in African countries. Lancet Glob Health. 2021;9:e5889. DOIPubMedGoogle Scholar
  10. Lumley  SF, Wei  J, O’Donnell  D, Stoesser  NE, Matthews  PC, Howarth  A, et al.; Oxford University Hospitals Staff Testing Group. The duration, dynamics, and determinants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody responses in individual healthcare workers. Clin Infect Dis. 2021;73:e699709. DOIPubMedGoogle Scholar
  11. Nkuba  AN, Makiala  SM, Guichet  E, Tshiminyi  PM, Bazitama  Y, Yambayamba  M, et al. High prevalence of anti-SARS-CoV-2 antibodies after the first wave of COVID-19 in Kinshasa, Democratic Republic of the Congo: results of a cross-sectional household-based survey. Clin Infect Dis. 2022;74:88290. DOIPubMedGoogle Scholar
  12. The World Bank. Cameroon: world development indicators. 2019 [cited 2021 Nov 26].
  13. Mandolo  J, Msefula  J, Henrion  MYR, Brown  C, Moyo  B, Samon  A, et al. SARS-CoV-2 exposure in Malawian blood donors: an analysis of seroprevalence and variant dynamics between January 2020 and July 2021. BMC Med. 2021;19:303. DOIPubMedGoogle Scholar

Main Article

Page created: April 03, 2022
Page updated: May 22, 2022
Page reviewed: May 22, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.